SIRT3 Modulating Compounds for Mitochondrial Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current activators and inhibitors of SIRT3, a key regulator of mitochondrial metabolism, have limitations in their therapeutic applications due to unclear mechanisms and lack of effective compounds for modulating SIRT3 activity.
Innovation Solution
Development of compounds of Formulas I and II, which are designed to modulate SIRT3 activity by binding to specific sites on the enzyme, thereby activating or inhibiting its function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to modulate SIRT3 activity by binding to specific sites, then therapeutic efficacy is improved, but mechanism understanding remains unclear
Solution Approach 1:
The patent uses structurally characterized compounds as intermediaries to bridge the gap between observed therapeutic effects and unknown mechanisms. By providing detailed structural information and binding site identification, these compounds serve as mediators that enable further mechanistic studies while delivering therapeutic benefits.
Solution Approach 2:
The patent applies parameter changes by optimizing compound structures (Formulas I and II) to achieve specific binding affinities and modulation potencies. By systematically varying molecular parameters such as substituent groups and structural features, the patent improves therapeutic efficacy while creating a framework for understanding structure-activity relationships.
2Ease of operation
If SIRT3 modulation is achieved through compound binding, then enzyme activity is controlled, but selectivity and specificity remain challenges
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that target particular regions of the SIRT3 enzyme. The formulas include defined aromatic groups (Ar1), substituent patterns (R1-R7), and structural motifs that confer localized binding specificity to the enzyme's active site or allosteric regions, thereby improving selectivity.
Solution Approach 2:
The patent segments the compound structure into distinct functional regions (aromatic core, substituent groups, linker moieties) that can independently contribute to binding specificity. This segmentation allows for rational design of selective inhibitors or activators by optimizing individual segments for specific interactions with SIRT3.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrated significant modulation of SIRT3 activity, with some exhibiting up to 66.3% inhibition of deacylation activity, and are expected to have EC50 values in the 10-20 μM range, indicating potential therapeutic efficacy.
Implementation Method 1
Sirt3 is a NAD+ dependent lysine deacylase, requiring the cofactor NAD+ to remove acyl groups from lysine groups of its substrates. The acetylated substrate and the NAD+ cofactor bind in between the two domains forming a stabilized cofactor binding loop.
Data Source
AI summary
In one aspect, compounds modulating sirtuin activity are described herein. Sirtuin modulation by compounds described herein includes sirtuin activation and sirtuin inhibition. Modulation of sirtuin activity includes sirtuin activation and/or sirtuin inhibition. In some embodiments, a sirtuin modulating compound and/or salt thereof is of Formula I described herein.